Pharmacotherapy for T2D (i.e., metformin, glipizide, rosiglitazone, insulin, or acarbose) reduces serum SAA levels in T2D subjects (9, 139, 149). The gene discussed is SAA2; the disease is type 2 diabetes mellitus.